Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $42.00.

TEVA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th.

Insider Buying and Selling

In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the sale, the executive vice president directly owned 65,621 shares of the company’s stock, valued at $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 259,831 shares of company stock worth $9,091,659. 0.54% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of large investors have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $25,000. Cornerstone Planning Group LLC increased its position in Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after buying an additional 755 shares during the period. Allworth Financial LP lifted its stake in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 1.9%

Shares of NYSE:TEVA opened at $36.04 on Tuesday. Teva Pharmaceutical Industries has a 52 week low of $16.26 and a 52 week high of $37.35. The company’s 50 day moving average is $33.28 and its two-hundred day moving average is $32.86. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. The company has a market cap of $42.00 billion, a PE ratio of 60.07, a P/E/G ratio of 3.78 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. Equities analysts predict that Teva Pharmaceutical Industries will post 1.96 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.